TL;DR: Journals disagree on BPC-157: a 2025 review and rebuttal debate angiogenesis, and a 2026 AJSM primer finds no high-quality human evidence.
BPC-157 Evidence Dispute: What Three Recent Papers Say
What Is the BPC-157 Literature Dispute?
Three recent publications give researchers a useful, if uncomfortable, picture of where the BPC-157 evidence base stands. In 2025 the journal Pharmaceuticals carried a literature and patent review of the pentadecapeptide by Józwiak and colleagues, followed in the October issue by a published comment from Sikiric and colleagues and a reply from the review authors.[1][2][3] In 2026 the American Journal of Sports Medicine added a clinician-facing primer on injectable peptides that reaches a blunt conclusion about the human data.[4]
Taken together they do not show that BPC-157 is inactive in the laboratory. They show that the field disagrees about how to weigh a large preclinical literature, and that independent human evidence is still missing. For anyone designing in vitro experiments with BPC-157, that distinction shapes which questions are worth asking.
What Did the 2025 Pharmaceuticals Review Examine?
Józwiak et al. A narrative review of the scientific and patent literature on BPC 157, covering its reported biological activities across organ systems and the status of related intellectual property.[1]
Pharmaceuticals 2025;18:185. Open access: PMC11859134
Reviews of this kind are valuable because they map claims rather than create them. The Józwiak paper catalogues the reported mechanisms of BPC 157, including effects described on endothelial cells, nitric oxide signalling and growth-factor expression, and places them next to the patent landscape.[1] Our BPC-157 research overview covers the same mechanistic ground from the compound side.
What Did the Comment and the Reply Argue?
The comment, titled BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions, was written by Sikiric and colleagues, the group that has produced most of the primary BPC 157 literature. As the title signals, it argues that the peptide modulates angiogenesis and nitric oxide pathways rather than simply driving them, and so should not be read as a straightforward pro-angiogenic risk.[2]
The reply from Józwiak and colleagues, published in the same issue, makes two points that matter to researchers.[3] First, it states that speculation about angiogenic effects and possible tumour-promoting properties is a legitimate scientific concern that has not been experimentally resolved. Second, it notes that a large majority of indexed records on BPC 157, over 80% by the authors' count, are linked to a single research group. We summarise those points as reported in the reply; readers should consult the full text before citing either figure.
The open mechanistic question
Whether "modulation" of angiogenesis and nitric oxide pathways is context-dependent is exactly the sort of question cell-based and ex vivo models can address, provided the controls are independent of the original group's assays.
The concentration problem
When one group authors most of a literature, replication and independent confirmation carry unusual weight. A consistent finding from a single laboratory is not the same evidentiary object as the same finding from three.
What Does the 2026 AJSM Primer Add on Human Evidence?
Mayfield, Bolia, Feingold, Lin, Liu, Hatch, Gamradt and Weber. A narrative primer on injectable peptides discussed in orthopaedics and sports medicine, including BPC-157, TB-500, CJC-1295 with ipamorelin, tesamorelin and GHK-Cu.[4]
American Journal of Sports Medicine, 2026. DOI: 10.1177/03635465251357593
The primer reports that BPC-157 has shown potential in tendon and muscle repair models but that these findings are largely unvalidated in humans. The only human report it identifies is a single case series of intra-articular knee injections, which the authors say has significant methodological flaws and no controls. It states that there is no high-quality clinical evidence in human subjects and no large multicentre trial examining safety or long-term use.[4]
For the other compounds in its scope, the authors note that tesamorelin has no supporting orthopaedic evidence and that GHK-Cu lacks clinical data for musculoskeletal conditions.[4] That is consistent with the August 2026 JBJS Reviews analysis we summarised, which reached a similar position from a different search strategy.
| Paper | Type of evidence | Main takeaway |
|---|---|---|
| Józwiak et al., 2025 | Literature and patent review | Maps reported mechanisms and patents |
| Sikiric et al., 2025 | Published comment | Argues pathways are modulated, not simply stimulated |
| Józwiak et al., 2025 (reply) | Published reply | Angiogenesis question unresolved; literature concentrated in one group |
| Mayfield et al., 2026 | Clinician-facing primer | No high-quality human evidence identified |
How Does This Differ From Licensed Pharma Development Such as Retatrutide?
The contrast is useful for keeping categories apart. Retatrutide is an investigational triple-agonist developed by Eli Lilly. It has progressed through a multi-trial Phase 3 programme, with peer-reviewed publication of results, such as the TRIUMPH-2 report we covered in our Lancet publication guide, and a regulatory filing planned by the sponsor. That is third-party pharmaceutical research, and it is not a statement about any research-use reagent.
BPC-157 has no sponsor-led programme of comparable scale. The only controlled human work we have tracked is the registered randomised trial described in our hamstring-strain trial guide, and the regulatory debate is covered in our PCAC July 2026 guide. The two compounds should not be read across: different evidence, different regulatory status, different questions.
What Should Researchers Take From the Dispute?
Three practical points follow for laboratory work. First, treat mechanistic claims about angiogenesis and nitric oxide as hypotheses to test, using appropriate controls and, where possible, independent assay systems. Second, prefer designs that could falsify a claim, not only reproduce it. Third, characterise your material: results are only interpretable if the peptide in the vial is what the label says. Our guides on reading a certificate of analysis and how peptides are tested explain what batch documentation should show.
All compounds named are supplied as research reagents only. None is a medicine and none has been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- Józwiak M, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals. 2025;18:185. PMC11859134
- Sikiric P, et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Pharmaceuticals. 2025;18(10):1450. mdpi.com/1424-8247/18/10/1450
- Józwiak M, et al. Reply to Sikiric et al. Pharmaceuticals. 2025;18(10):1451. mdpi.com/1424-8247/18/10/1451; PMC12567171
- Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Hatch GFR, Gamradt SC, Weber AE. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026. DOI: 10.1177/03635465251357593
Frequently Asked Questions
What is the BPC-157 literature dispute?
In 2025 the journal Pharmaceuticals published a literature and patent review of BPC 157 by Józwiak and colleagues, a comment on it by Sikiric and colleagues, and a reply from the review authors. The exchange concerns how to read the preclinical evidence on angiogenesis and nitric oxide signalling, and how much of that evidence comes from a single research group.
Is there high-quality human evidence for BPC-157?
According to a 2026 primer in the American Journal of Sports Medicine (Mayfield et al.), no high-quality clinical evidence in human subjects supports BPC-157. The authors describe the orthopaedic literature as limited to animal studies and one human case series with significant methodological limitations.
Why does angiogenesis matter in the BPC-157 debate?
BPC-157 is reported to act on endothelial and growth-factor pathways. The review authors state that concern about possible effects on angiogenesis and tumour biology is a legitimate scientific question that has not been experimentally resolved, which is one reason they call for independent, controlled study.
Does this dispute change how Velox Peptides supplies BPC-157?
No. BPC-157 is supplied solely as an HPLC-verified in vitro research reagent with batch documentation. The papers summarised here are third-party academic literature and say nothing about any Velox product. Nothing here is a claim of benefit, and no product is for human or veterinary use.
How is BPC-157 different from retatrutide in evidence terms?
Retatrutide is a licensed-pharma development candidate that has been through a multi-trial Phase 3 programme (TRIUMPH), with results in the peer-reviewed literature and a regulatory submission planned by Lilly. BPC-157 has no equivalent programme. They sit in different regulatory and evidentiary categories and should not be read across.